Stem Cell-Derived Extracellular Vesicles Show Promise for Respiratory Disease
Researchers are exploring whether stem cell-derived extracellular vesicles could offer safer, targeted therapies for respiratory diseases, but technical hurdles remain.
Key findings
- Extracellular Vesicles (EVs) act as cell-free drug carriers, immunomodulators, and tissue repair agents
- Current isolation and clinical translation of EVs face technical and regulatory challenges
- Clinical trials confirm safety and early efficacy of EV-based treatments in respiratory conditions
Noncommunicable diseases, and particularly respiratory disorders, are expected to become an even greater global health burden in the coming decades. Many conventional therapies struggle with limited targeting and delivery efficiency. Recent research points to extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) as a compelling new approach for treating respiratory diseases, providing both targeted delivery and broad immunomodulatory effects.
Stem cell-based therapies have already shown safety and some efficacy in acute respiratory distress syndrome (ARDS), with intravenous administration of MSCs supporting lung function and inhibiting disease progression in clinical trials. However, the field has faced challenges: the low engraftment and survival of MSCs in lung tissue have limited their sustained therapeutic impact.
Researchers have found that much of the benefit provided by MSCs may actually be due to their release of EVs. These nano-sized vesicles—typically 50–200 nm in diameter—can transfer a variety of molecules, including mRNA, microRNA, proteins, and lipids to target cells. As a result, EVs can influence gene expression, reduce inflammation, and promote tissue repair, all while exhibiting low immunogenicity and no inherent tumorigenic risk.
A range of technologies is available for isolating EVs, such as differential and density gradient ultracentrifugation, immunomagnetic bead capture, tangential flow filtration, and size-exclusion chromatography. Each method carries trade-offs in terms of purity, yield, and complexity. The lack of standardized protocols for EV isolation and quality control is a significant barrier to clinical translation, as variabilities in EV preparations can affect therapeutic outcomes.
Potential in Therapy
In respiratory disease models, MSC-derived EVs have demonstrated efficacy across several domains. In acute lung injury, for instance, EVs have been shown to reverse damage by modulating oxidative stress response pathways and enhancing NF-κB signaling. In chronic lung conditions, EVs can regulate the immune system, promote vascular regeneration, and even influence the development and progression of lung cancer by affecting tumor signaling pathways and immune evasion.
Beyond tissue repair, EVs have attracted attention as nano-carriers for targeted drug delivery. Studies have explored EVs as vehicles for gene-editing tools like CRISPR-Cas9, as well as for antiviral agents during COVID-19. Successful drug delivery depends on the choice of loading strategy (e.g., genetic engineering, electroporation, or chemical conjugation), the preservation of EV membrane integrity, and the release kinetics of the payload. Routes of administration also matter: while intravenous and nebulized inhalation are common, each method has its own advantages and limitations regarding efficiency and targeting.
EVs also play a role in immune modulation, affecting both innate and adaptive immune cell populations. They can suppress unwanted immune responses, promote regulatory T cell populations, and facilitate the clearance of pathogens. Researchers found that EVs can reduce the proliferation of effector immune cells and increase the production of anti-inflammatory cytokines, potentially mitigating the cytokine storm in severe viral infections such as COVID-19.
Another major area of application is in oncology, where EVs from cancer or immune cells can function as both biomarkers (liquid biopsy) and drug carriers. Their surface proteins can be engineered for enhanced targeting, and their cargo can influence the immune microenvironment, tumor cell dormancy, and metastasis. Clinical studies suggest that combining EV analysis with other markers, such as circulating tumor DNA, can improve diagnosis and personalized treatment strategies for lung cancers.
Clinical trials have begun to validate the safety and early efficacy of MSC-EV therapies in humans. Trials in COVID-19 patients have reported improved outcomes and no significant adverse events for those receiving EV-based therapies, whether via inhalation or intravenous injection. Engineered EV products are under investigation for chronic obstructive pulmonary disease, where they appear to modulate pulmonary immune responses and improve symptoms.
Challenges Ahead
Despite these advances, several challenges remain. The field lacks standardized, scalable, and cost-effective methods for EV isolation and production. EVs are prone to instability during storage and may face rapid clearance in vivo. Heterogeneity among EV populations further complicates both research and clinical applications. Long-term safety data, particularly with repeated or high-dose exposures, remains limited.
Want to keep up on regenerative medicine trials? Get the weekly newsletter here
Zu, Tingting MMa; Gao, Meng MMa; Liu, Baohe MMa; Zhang, Xuejing MMa; Wu, Fuling MDa,*. Recent developments of mesenchymal stem cell-derived extracellular vesicles in respiratory system diseases: A review. Medicine 104(29):p e43416, July 18, 2025. | DOI: 10.1097/MD.0000000000043416
